INNOVANCE reagents support management of COVID-19 patients

INNOVANCE reagents support management of COVID-19 patients

Siemens Healthineers’s INNOVANCE assays help improve efficiencies, workflow and resource management following a COVID-19 diagnosis. In hospitalised COVID-19 patients, elevated D-dimer levels have been...

Supplied by Siemens Healthineers


Siemens Healthineers’s INNOVANCE assays help improve efficiencies, workflow and resource management following a COVID-19 diagnosis.

In hospitalised COVID-19 patients, elevated D-dimer levels have been found to be strongly associated with disease severity and even mortality reflecting the procoagulant status and high thrombotic risk observed in many COVID-19 patients. Therefore, the monitoring of D-dimer levels is recommended for hospitalised COVID-19 patients to stratify their thrombotic risk including testing for deep vein thrombosis and pulmonary embolism and guiding treatment over the course of the disease.

Treating COVID-19 patients with anticoagulants has been associated with improved outcomes, both in and out of the intensive care unit setting.

Accurate antithrombin measurement in COVID-19 patients undergoing anticoagulant treatment may be useful to determine the efficacy of anticoagulant therapy as antithrombin levels might be reduced.

Siemens Healthineers has a comprehensive portfolio of assays for detection and monitoring of coagulation disorders.

For more information, visit: https://www.siemenshealthineers.com/hemostasis/ innovance-reagents-for-coagulation-disorders


Contact form

Get in touch directly with the above supplier

Your email address will not be communicated to any third party other than the above supplier for the purpose of fulfilling this enquiry. For more information: read our privacy policy.